Valuation: Axsome Therapeutics, Inc.

Market Cap 1.02TCr 896.71Cr 846.91Cr 771.8Cr 1.44TCr 98TCr 1.46TCr 10TCr 3.93TCr 50TCr 3.84TCr 3.75TCr 1,60800Cr P/E 2026 *
-72.6x
P/E 2027 * 43.9x
Enterprise Value 1.01TCr 883.27Cr 834.21Cr 760.23Cr 1.42TCr 96TCr 1.43TCr 9.98TCr 3.87TCr 49TCr 3.78TCr 3.7TCr 1,58400Cr EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.32x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week-6.11%
Current month-1.73%
1 month-5.06%
3 months-17.80%
6 months+20.59%
Current year+6.82%
1 week 189.05
Extreme 189.05
210.85
1 month 189.05
Extreme 189.05
229.62
Current year 152.28
Extreme 152.28
260.19
1 year 116.18
Extreme 116.1756
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Exercice

Chief Operating Officer

30,000 0.0573%
06/08/26 Exercice

Chief Executive Officer

13,980 0.0272%
01/07/26 Exercice

Chief Executive Officer

1,48,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-6.11%+68.17%+175.82% 1.02TCr
-1.00%+0.41%+41.86%-5.58% 7.87TCr
+2.08%+29.11%+708.13%+102.59% 7.94TCr
-1.21%+0.77%-10.63%-30.06% 5.95TCr
-1.80%-2.29%-13.07%+28.02% 4.65TCr
+1.18%+3.03%+9.11%+169.01% 4.66TCr
+0.55%+5.61%+67.76%-10.75% 3.36TCr
-0.44%-1.13%+51.71%+110.88% 2.51TCr
-0.10%+3.21%+4.89%+155.64% 2.21TCr
+0.05%-2.42%+57.59%+97.38% 1.53TCr
Average -0.37%+3.03%+98.55%+79.29% 4.17TCr
Weighted average by Cap. -0.51%+6.14%+153.36%+58.13%

Financials

2026 *2027 *
Net sales 96Cr 85Cr 80Cr 73Cr 136.34Cr 9.24TCr 137.31Cr 956.37Cr 370.42Cr 4.72TCr 362.07Cr 354.24Cr 15TCr 154.77Cr 135.81Cr 128.27Cr 116.89Cr 218.82Cr 15TCr 220.38Cr 1.53TCr 594.5Cr 7.58TCr 581.1Cr 568.53Cr 24TCr
Net income -14Cr -12Cr -12Cr -11Cr -20Cr -1.35TCr -20Cr -140Cr -54Cr -691.22Cr -53Cr -52Cr -2.22TCr 24Cr 21Cr 20Cr 18Cr 35Cr 2.34TCr 35Cr 242.59Cr 94Cr 1.2TCr 92Cr 90Cr 3.85TCr
Net Debt -15Cr -13Cr -13Cr -12Cr -22Cr -1.47TCr -22Cr -151.93Cr -59Cr -750.14Cr -58Cr -56Cr -2.41TCr -43Cr -38Cr -36Cr -32Cr -61Cr -4.12TCr -61Cr -426.57Cr -165.22Cr -2.11TCr -161.49Cr -158Cr -6.77TCr
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
25/26/25 $195.09 -0.48% 8,38,181
24/26/24 $196.03 +1.33% 3,86,176
23/26/23 $193.45 -4.75% 9,12,995
22/26/22 $203.10 -1.16% 2,99,785
21/26/21 $205.49 -1.10% 5,43,471
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
195.09USD
Average target price
285.22USD
Spread / Average Target
+46.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock